Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (26721)	12/1/1998 10:22:00 AM
From: Henry Niman	Respond to of 32384

Yesterday's announcement is summarized in Bloomberg's equity preview for today: Ligand Pharmaceuticals Inc. (LGND): The biotechnology company said it moved closer to U.S. Food and Drug Administration approval of its Panretin gel treatment for an AIDS-related skin cancer. After the market closed, the startup biotechnology company said the FDA sent it a so-called approvable letter, which generally means the agency intends to approve a drug after it resolves remaining issues. In this case, the company said it expects a final decision by the end of December after the FDA reviews ''additional chemistry information'' and the company and FDA agree on what should be on the drug's label. Ligand fell 1/4 to 9 15/16.